Lasa Supergenerics Limited (LASA) — Insider Trading | 18 July 2026

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Lasa Supergenerics obtains SDD compliance certificate for Q1 FY27
💡 Investor Takeaway
The company maintains robust insider trading controls with no recent violations, supporting regulatory confidence.

Lasa Supergenerics Limited received a Structured Digital Database (SDD) compliance certificate from its compliance officer for the quarter ended June 30, 2026, confirming adherence to SEBI insider trading regulations, including UPSI capture, access controls, audit trails, and non-tamperability measures, with no observed non-compliance during the period.

📄 View Original Announcement (PDF)

About Lasa Supergenerics Limited (LASA)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹31.41 Cr ROE: -20.2% ROCE: -17.9%

View full LASA stock details →

📡 Get AI alerts when LASA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track LASA — Free

📊 More LASA filings

See all LASA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when LASA files new disclosures

Track LASA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track LASA — Free

Free account · 2 AI queries/day